Market Size of Global Gastroparesis Drug Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Gastroparesis Drug Market Analysis
The Gastroparesis Drug Market is expected to register a CAGR of 4.5% over the forecast period.
In patients with chronic gastrointestinal illnesses, COVID-19 initially created a lot of complications as viruses have historically been implicated in complications of gastrointestinal disorders, including gastroparesis. According to an article published by PubMed Central in March 2022, patients suffering from COVID-19 can present with a variety of GI symptoms, such as diarrhea, anorexia, nausea, and vomiting, and can be associated with several GI conditions such as liver injury, GI bleeding, acute cholecystitis, and acute pancreatitis among others. Moreover, according to an article published by PubMed in December 2022, the COVID-19 pandemic significantly reduced the number of gastrointestinal endoscopy procedures necessary for diagnosing gastroparesis. Thus, the increasing complications of gastroparesis and the reduction in gastrointestinal endoscopy procedures significantly impacted market growth. However, as the pandemic has subsided currently, the studied market is expected to have stable growth during the forecast period of the study.
Several factors, such as the increase in the incidence rate of the diabetic population, the rise in the number of surgical procedures, and the growth in the geriatric population, are among the key driving factors for the gastroparesis drug market. Gastroparesis is a disorder affecting mostly type1 and type2 diabetic patients. In this disorder, the stomach takes too long to empty its contents. Drugs, such as erythromycin, antiemetics, and Reglan, are prescribed for treating gastroparesis. Moreover, according to the data from clinicaaltrials.gov in December 2022, there are 60 ongoing clinical trials for gastroparesis drugs due to the high prevalence of type1 type2 diabetes. This drives the demand for these drugs and will further fuel the overall market to a certain extent.
Moreover, according to an article published by Frontline Medical Communications Inc. in April 2022, it is estimated that classic gastroparesis has a prevalence of about 10 per 100,000 population in men and 30 per 100,000 in women, and women are being affected 3 to 4 times more than men. A Major Risk factor for classic gastroparesis is diabetes mellitus (DM), which affects up to 5% of patients with type 1 DM. Thus, the increasing prevalence of gastroparesis is driving the market's growth.
Furthermore, leading manufacturers continuously fund research and development (R&D) projects to introduce new approaches to existing drug therapy. For instance, in October 2021, Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, announced that the United States FDA had cleared them to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis, which is an unmet medical need condition for which patients who need an alternative and safer treatment options.
Thus, the factors above, such as the rising prevalence of gastroparesis and continuous funding for research and development (R&D) projects to introduce new approaches to the existing drug therapy of gastroparesis, are expected to enhance the market growth. However, the time-consuming regulatory process and side effects of gastroparesis drugs may hamper the market's growth during the forecast period.
